Click on image to view larger version.

Figure 3 Effect of Statin Therapy According to KIF6 Trp719Arg in 3 Studies

Effect of statin therapy on fatal coronary heart disease or nonfatal myocardial infarction in the CARE trial, coronary heart disease in the WOSCOPS trial, and death or major cardiovascular events in the PROVE IT-TIMI 22 trial according to KIF6 719Arg carrier status. In both the CARE trial, a secondary prevention study, and the WOSCOPS trial, a primary prevention study, the effect of pravastatin (40 mg) was compared with placebo. In the PROVE IT-TIMI 22 trial, a secondary prevention study, the effect of atorvastatin (80 mg) was compared with pravastatin (40 mg). We used Cox proportional hazards models in the CARE and PROVE IT-TIMI 22 trials and conditional logistic regression in the nested case-control study of the WOSCOPS trial. CI = confidence interval.